Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Company filed and said they were selling 2.2 million. My guess is this selling pressure is from all the crowd funding investors. They have been sitting on these shares for 5 years or more. I think the company is legit long term. I also don’t believe the company is scamming anyone. They have long term goals. Just need to execute them.
Yes you are correct. Been on since around 2018
Yes. Let’s go Kscp
Yes. You are right. Been a hold since 2017.
Me too. Company sold 2.2 million shares. Hopefully that was today and reason for a lot of this selling pressure
They are working on contracts with the military. They passed all the security checks.
Related Party Transactions:
A related party is generally defined as (i) any person that holds 10% or more of our membership interests including such person's immediate families, (ii) our management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with us, or (iv) anyone who can significantly influence our financial and operating decisions. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.
Income Taxes:
Here is the statement in the 10k that explains the definition of a controlling party. If Ross owns 25 million shares or 10% of 250 million shares it would be in this 10k
Is this what your talking about? If someone owned 10% of the company it would be noted in the 10k and it’s not. Cause again here it’ states this debt 3.1 million shares was settled.
You show me where Ross owns 10% of DCGD
NOTE 4. ACCOUNTS PAYABLE AND ACCRUALS
On April 23, 2018, we issued 3,100,000 shares of our common stock valued at $4,650 to a creditor of ours in settlement of the balance of consulting fees due to him.
As of April 30, 2019 and 2018, $83,000 of the accounts payable and accruals balance related to legal fees owed to a single creditor. Effective May 2, 2018, we entered into an agreement with the creditor and the two shareholders controlling the majority of our outstanding shares of common stock pursuant to which all parties agreed that in the event that the two controlling shareholders were to sell their shares, the outstanding liability to the creditor will be satisfied in full out of the sales proceeds received by the two controlling shareholders. The original term of the agreement expired at December 31, 2018. However, effective December 31, 2018 the term of the agreement was extended to April 30, 2019, and effective April 30, 2019, the term of the agreement was further extended to August 31, 2019.
As further discussed in Note 10. Subsequent Events below, effective June 25, 2019, the entire balance of accounts payable and accruals outstanding at April 30, 2019 was satisfied in full out of the sales proceeds received by the two controlling shareholders on the sale of their shares to GRN Funds, LLC.
It starts at the bottom effective June 25.......
NOTE 10. SUBSEQUENT EVENTS
The Company evaluated subsequent events after April 30, 2019 through the date these financial statements were issued and has determined there have been no subsequent events for which disclosure is required, other than as disclosed below.
On June 20, 2019, GRN Funds, LLC, a Washington limited liability company, and its manager and Chief Executive Officer, Justin Costello, purchased a total of 139 million shares of the Company’s common stock representing 55.65% of its issued and outstanding shares, in a private transaction with Stephen Flechner and David Cutler. As a result of the closing of the transaction on June 25, 2019, GRN Funds, LLC and Mr. Costello acquired a majority of the issued shares eligible to vote. The total purchase price of $300,000 was paid in cash by GRN Funds, LLC. As a condition to the closing of the transaction, the Registrant’s Directors Mr. Stephen Flechner and Mr. Ralph Shearing resigned, and Mr. Flechner resigned as Chief Executive Officer and President, and Mr. Justin Costello was concurrently named Director of the Company, President and Chief Executive Officer.
Effective June 25, 2019, all outstanding balances of accounts payable and accruals, accruals-related parties and loan-related parties were satisfied in full out of the sales proceeds received by the two controlling shareholders on the sale of their shares to GRN Funds, LLC.
F- 13
Honestly I don’t usually respond to the nonsense and I don’t really care wether anyone believes me or not. The 10k links are all over this site. I believe it’s laid out in section 4A
Rug your full of shit. Ross doesn’t own any DCGD stock unless he bought some after grn bought it out. It’s clearly laid out in the 10k
Quit lying.
He might be but has nothing to do with DCGD stock. I would recommend you read the 10k that was filed but you won’t since the facts don’t fit your narrative. But a little hint. It clearly states any positions owed to Ross were settled with the grn fund purchase price of $300k
Try again.
Thanks B55. Sound info and appreciate all the hard work with site.
Also Canopy, Aurora, and most recently Hexo are all on nasdaq. There is a few others but not many
Thanks for the informative post.
Another consideration is the farming hemp bill which the holding company is getting involved. This creates some loop holes in federal regulations as well for uplisting and also opens up distribution opportunities across state lines.
Amen Whip.
Let the man work. We probably won’t see anything until next week.
DCGD $$$$$!!!
And the huge ones are Halliburton, Bechtel, and Raytheon. Most people haven’t even heard of the first 2. Huge defense contractors. Built Hoover damn, nuclear sites worldwide etc.
Welcome backbPauly.
Great post Arca.
Hhhmmm. So according to the 10k filed with the SEC. Rosses don’t own chit. All debs settled and closed via the 300k in cash paid to the old owners.
Great post CB
DCGD $$$$$$$&$$$
Forbes crushes seeking alpha BS and fake news
https://www.forbes.com/sites/richardlevick/2018/08/20/does-seeking-alpha-enable-anonymous-authors-to-spread-fake-news/amp/?__twitter_impression=true
10k filed. Dated and accepted with time stamp. 8/14/2019. 16:27
Viewed from sec.gov on PC. Tried to go to it on phone and website must be getting hammered. Can’t get to filing page to post link.
One small piece filled
Go DCGD$$$$$$
Hit the ask 5k more.
DCGD$$$$$$$
If I was why bring it up. Just an observation. When I first bought in around July 7 it was 36k it dropped to 14k until this week
Has anyone noticed according to ihub there is 706k new short positions as of this week. Last week it was 14k.
Yes, well said. They also need to remove THC from the schedule 1 drugs list like they did for CBDs recently
You are most likely correct with this assessment. However the most probable reason is because cannabis is still federally illegal in the US. Making banking illegal too for cannabis companies. There are a small few on US exchanges but theses companies are still not readily available for trading with most 401ks, etc. The house did recently pass a new cannabis banking law and it’s in the senate. This will open some doors.
Hey all, been following for awhile and have noticed a lot of posts regarding the patents. My cousin is a partner and patent attorney so I asked him to take a look. This is legit info directly from him and pasted below. Not great news but not terrible.
I did some digging, but was unable to find a publication of any patent application that they might have. Searching by potential owner, inventors (e.g., Arup Sen) and keywords did not come up with anything. As discussed below, the patent application may not be publicly available yet or I may have missed it if it’s held by another entity or has named inventors who are not associated with Sproutly or Infusion Biosciences.
As you noted, it looks like the APP tech was developed by Infusion Biosciences, which Sproutly apparently acquired in 2018. The Infusion Biosciences website (https://infusionbiosciences.com/our-company-3/ [infusionbiosciences.com]) indicates an initial patent application being filed December 2016 with an “updated” patent application being filed in May 2017.
It’s not entirely clear, but my guess is that they filed a first provisional patent application in 12-16 and then filed a second updated provisional patent application or possibly a non-provisional patent application in 5-17. By default, US patent applications are held secret for 18 months from their earliest priority date (in this case 12-16), but applicants can request that the application remain secret until the application issues as a patent.
Since they still cite the technology as “patent pending” and it doesn’t seem like the patent application is public yet, this suggests that the application is in the middle of being examined or is waiting to be examined at the USPTO. It can take 1-3 years for examination to begin once the non-provisional is filed (either 5-17 or 12-17 at the latest in this case) and examination can potentially last several years, so it’s not unexpected for the application to still be pending.
One interesting thing that I also found was that Infusion Biosciences may be licensing the APP tech to other folks (e.g., TrueAeroGrow -https://www.trueaerogrow.com/aqueous-phytorecovery [trueaerogrow.com] ), so Sprouly may not be the only ones using the technology.
Also, I would take a lot of what they say about the patent application and its potential protection with a grain of salt. There is no guarantee that the application will ever issue as an enforceable patent, and even if a patent does issue, there is no guarantee that it would be so broad as to cover all viable methods of making water soluble cannabis products or generally infusing consumables with water based CBDs and THC (in fact, patents are typical not this broad). It’s possible that the patent could be narrow such that it would be easy to design around or otherwise allow others to easily enter the market with similar production methods and products. Very speculative at this point since we don’t know anything about the patent application.